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Myocardial infarction (MI), caused by the occlusion of the left ventricular coronary artery,
may lead to massive loss of cardiomyocytes and eventually heart failure. To repair MI, one key
issue is to compensate for the loss of cardiomyocytes in the MI site. Notably, cardiomyocytes are
mature cells with limited proliferation capability. Another issue in MI repair is to improve the local
ischemic condition at the MI site so as to provide the cells with nutrition and oxygen, where the
revascularization or the renewal of the small vessels (or angiogenesis) is critical. To address the
issues, the proposed study aims to develop injectable alginate hydrogels with growth factor/living
cells for MI repair. To be more specific, two specific strategies were developed, which were 1)
to co-deliver 6-Bromoindirubin-3-oxime (BIO) and insulin-like growth factor (IGF-1) by means
of nanoparticles and 2) to encapsulate living stem cells. BIO is a small molecular drug that can
promote the regeneration of cardiomyocytes and IGF-1 is able to stimulate the angiogenesis.
In the development of strategy 1), both BIO and IGF-1 were encapsulated in gelatin nanopar-
ticles, which were later cross-linked with the oxidized alginate to form a novel hybrid hydrogel
system. The fabricated nanoparticles were then subjected both in vitro and in vivo characterization.
The results have shown that the growth factors can continue to release over 110 hours in vitro and
last for 45 days in vivo. The in vivo results have also shown that the hybrid system could enhance
the proliferation of cardiomyocytes in situ and could promote revascularization around the MI sites,
allowing improved cardiac function. Taken together, the strategy of co-delivering of BIO and IGF-1
is promising for MI repair.
In the development of strategy 2), two types of alginate hydrogels, based on self-crosslinking
(SCL) and calcium ion crosslinking (Ca2+ ), were synthesized in varying formulations; hydrogels
encapsulated living muscle-derived stem cells (MDSCs) and their performance was evaluated in
terms of optimizing cell viability during the injection process as well as the live/dead ratio af-
ter long-term cultivation. The morphology of the hydrogel-encapsulated cells was characterized
by scanning electronic microscopy (SEM) and live/dead cells were examined using an 3-(4,5-
dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide staining (MTT) assay. The mechanical
properties of the hydrogels were also determined via a rheometer, to identify their influence on cell
viability during the injection process and with respect to long-term cultivation. The results show
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that living cells are able to survive in both types of hydrogels and SCL hydrogel in particular is
better for the living cells in long term.
To sum up, this study illustrates that both strategies are promising in MI repair by presenting
a non-invasive method of injecting biocompatible and biodegradable hydrogel with growth factors
and living cells for supplementing cells and angiogenesis for further enhancing heart function in
MI rats. These strategies could be adopted and used in clinical applications to human patients.
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1 Introduction and Objectives
1.1 Background of Myocardial Infarction
Myocardial infarction (MI), commonly known as heart attack, results from interruption of the blood
supply to a part of the heart. This is most commonly due to occlusion of the coronary artery. If left
untreated, the ischemia or resulting restriction in blood supply may cause damage or death of the
myocardium or cardiac muscle tissue, thus leading to heart failure. According to the latest report
from the World Heath Organization [1], MI and other cardiovascular diseases are the leading causes
of death worldwide.
Hearts are primarily composed of the myocardium and coronary arteries. The myocardium
has extremely limited regeneration potential [2, 3]. Supplied with oxygen- and nutrient-rich blood
through the coronary arteries, the myocardium continuously contracts and relaxes so as to pump
blood throughout the body. After MI, the ischemic myocardium ceases to function properly due to
the loss or death of cardiomyocytes, i.e., the cells of which the myocardium is comprised. This is
further accompanied by a ventricular remodelling process [4, 5] due to the degradation of the ex-
tracellular matrix (ECM) by matrix metalloproteinases (MMP) [6, 7] and scar tissue formation [8],
eventually leading to congestive heart failure [9].
Various therapies, including pharmaceutical interventions, have been exploited to slow down
the progression to heart failure. Unfortunately, these therapies do not restore function to the affected
myocardium [9, 10]. Heart transplantation is the gold standard to treat congestive heart failure but
is severely limited as an option due to the limited availability of donor organs. Moreover, the
immunological injection response in the hosts after the heart transplantation surgery is a potential
risk [11, 12] and a crucial factor lowering life quality of patients, which makes this therapy less
practical clinically.
With advances in tissue engineering, injection or implantation of tissue engineering cardiac
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constructs or scaffolds made from biomaterials and/or living cells into the affected myocardium
shows promise for improving MI repair.
1.2 Literature Review on Injection Strategies
1.2.1 Cardiomyoplasty and Cell Sources
A therapy is demonstrated through recent investigations into cellular cardiomyoplasty, wherein
cardiomyoblasts or other types of stem cells are directly injected into the injured heart, serving as
renewable cellular sources aiding in the repair of the damaged myocardium [3]. Studies working
on improvement in myocardial function by means of cardiomyoplasty have been demonstrated [3,
13, 14, 15].
Cardiomyocytes are mature mammal cells that are limited in regeneration [16, 17]. By trans-
planting exogenous cells into the damaged heart after MI, it is an important way to supplement the
cells for repairing MI [18]. Various stem cells show the ability to differentiate into cardiomyocytes
and proliferate as candidates of cells sources [19, 20].
Embryonic stem cells transplantation
Research has illustrated that embryonic stem cells can form new myocardium after transplanting
into normal or infarcted heart [21], and that stem cell derived cardiomyocytes can improve the
myocardial performance in MI rat models [22]. Also, due to the facts that embryonic stem cells
can from an efficient alternative substrate in MI rats hearts, the advantages for using these cells in
MI rats are as of preventing myocardial wall from thinning and improving the contractility [23].
As such, embryonic stem cells are considered as an appropriate cell type for supplementing cell
loss in MI heart. However, it is also noted by experiments that human stem cells cannot directly
form new myocardium after transplantation into MI rat hearts and may create teratoma. However,
they can attenuate post-MI scar thinning and left ventricular dysfunction [24]. Another previous
study indicated another disadvantage of embryonic stem cells in MI treatment is causing tumour
genesis [25]. Moreover, the source of embryonic stem cells is limited because these cells are still
not considered ethical for use in clinical trials.
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Bone marrow stem cells
Bone marrow stem cells retain the regenerative ability of forming new cardiomyocytes and coro-
nary vessels in MI rat models [26]. Moreover, they have more sources compared with embryonic
stem cells, which solves the deficiency of limited access of embryonic stem cells. Zhang et al. advo-
cate these aforementioned conclusions by illustrating the experimental results that nine days after
transplantation of bone marrow stem cells in MI mice, the new generated myocardium occupies
68% in the infarcted area [27]. Tanaka et al. state that heart function was improved, angiogenesis
was enhanced [28] and the regenerative ability for deriving into cardiomyocytes was improved af-
ter transplanting bone marrow mesenchyme stem cell into MI rats [29]. However, disadvantages of
bone marrow stem cells, such as difficult accessibility and disease-related malfunction, discussed
in these studies [30] [31] [32] have been noted.
Adipose derived stem cells
Adipose derived stem cells are promising candidates for repairing MI due to their high potential
ability for deriving into cardiomyocyte-like cells and improving heart function after being trans-
planted into MI rat’ hearts [33]. Adipose derived stem cells can be obtained from adipose tissue,
which guarantees the abundant resource [34]. This is proved by Choi et al.’s experimental results
that have shown modified heart function and enhanced vascularization as well as improved long-
term survival rate after transplanting adipose derived stem cells into acute MI rats [35, 36, 37]. On
the other hand, some research point out that mesenchymal stem cells from adipose tissue cannot dif-
ferentiate into real cardiomyocytes although the heart function is improved after being transplanted
[38].
Induced pluripotent stem cells
Induced pluripotent stem cells, another type of cells of high differentiation and proliferation ability
with a plentiful of access [39], may also be an appropriate cell type in MI repair. Experimental
results show that induced pluripotent stem cells maintain cell viability by inhibiting apoptosis via
Akt/Pten pathway in doxorubicin-induced cardiotoxicity [40]. Facts showing induced pluripotent
stem cells are beneficial for heart function repair after MI, such as in MI mice models the cardiac
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remodeling can be attenuated by the absence of induced pluripotent stem cells derived cardiomy-
ocyte sheets [41]. Jia et al. illustrate that heart function is improved by intramyocardial injection
of induced pluripotent stem cells in acute MI porcine models [42]. Similarly, heart repair and left
ventricular dysfunction can be ameliorated in acute and subacute MI rats respectively by intra-
myocardial delivery of induced pluripotent stem cells [43, 44]. However, shortages of induced
pluripotent stem cells are emerging and make it difficult when applying in MI repair. For example,
the reprogramming of induced pluripotent stem cells is still slow and inefficient [45], which costs
more time and energy to take usage of these cells than other cells. Another disadvantage is that the
immunological rejection responses are serious after transplanting induced pluripotent stem cells
[46].
Muscle derived stem cells
Muscle derived stem cells, owing to their characteristics of regeneration and great differentiation
potential into cardiomyocytes, are a kind of somatic stem cells which have plentiful of sources [47,
48]. Moreover, myosphere-derived progenitor cells have an extended period of proliferation time.
They can spontaneously differentiate into myotubes in differentiation media and into other meso-
dermal cell lineages in induction media [49]. Several previous studies reported that muscle derived
stem cells have good proliferative and adhesion properties. Muscle derived stem cells can improve
cell regeneration capacity and pumping ability of heart in chronic MI model without causing any
significant arrhythmias. Currently no obvious shortages have been reported of the application of
muscle-derived stem cells in MI repair. They are considered appropriate cell source type, though
the retention rate is still too low after transplanting into MI hearts.
1.2.2 Injectable Hydrogels
The cellular therapy faces a major problem. Typically, the cell injection process transplants cells
in an aqueous solution and, as such, does not provide cells with any environment or matrix for
attachment and protection. In such harsh conditions, the transplanted cells may be damaged [50,
51]. Furthermore, upon injection into the ischemic myocardium, cells experience a harsh hypoxic
environment that further negatively impacts cell viability [52, 53, 54, 55, 56]. As a result, most (90-
95%) injected cells die shortly after transplantation and only a small subpopulation plays a role in
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muscle regeneration [55, 56]. More recently, research has shown cell viability during injection can
be significantly improved if cells are encapsulated in hydrogels rather than suspended in aqueous
solutions [57, 56, 58, 59].
Hydrogels are cross-linked networks of polymers, such as fibrin and alginate, with high water
content between polymer chains [60, 61, 62, 63]. When used for cell encapsulation, hydrogels
provide a hydrated tissue-like scaffold or environment for cell attachment and protection, thereby
improving cell viability. Among various injectable hydrogels, alginate cross-linked in the presence
of calcium ions has been drawing considerable attention for use in MI repair, leading to enhanced
cell viability and proliferation as well as improved contractile function [64, 65, 66]. However, the
calcium-ion-cross-linked (CICL) alginate hydrogel has uncontrollable degradation kinetics [67, 68]
and poor cell adhesion and infiltration [61]. Recently, successful application of a new class of
hydrogels from oxidized alginate and gelatin, through a self-cross-linked (SCL) process, has been
reported for drug delivery and wound healing [64, 65]. Our group have begun to synthesize and
characterize SCL alginate hydrogels, and demonstrated them to be more suitable for MI repair than
CICL alginate hydrogels. One key objective of this MSc project is to expand our ongoing studies
to synthesize SCL alginate hydrogels for cell encapsulation in MI repair.
1.2.3 Controlled Release Strategies in MI Repair
Drugs or growth factors may be used in MI repair to stimulate cardiomyocytes to proliferate. For
this, drugs should be small molecule and should permeate into cells, meanwhile not cause toxic
effect. The challenge here is to control drug release rate or speed such that the drug concentration
can be maintained constant for the MI repair.
One feasible way to control the release speed is entrapping drugs by nanoparticles for gradually
releasing from particles [66, 69]. Another way for controlling the release speed is to cross-link
nanoparticles with scaffolds via chemical, combining or disconnecting chemical bonds [70, 71].
Hua et al. released diclofenac sodium through the drug delivery system of cross-linking Ca2+
with sodium alginate/poly (vinyl alcohol) by adjusting the pH value for heart function recovery
examination [72].
Controlled release can be applied in a broad manner, such as cell release with particular drugs.
Kasko et al. discussed repairing heart function via releasing living cells and drugs together, par-
5
ticularly patterned hydrogel has been fabricated based on two-photon lithography technique for
releasing cells in local MI area [73]. Due to plentiful applications of controlled release of nanopar-
ticles crosslinking with hydrogel, it is critical to manipulate the loading efficiency of nanoparticles.
Hamidi et al. proposed a new drug delivery model of valproate-loaded nanogels encapsulated
erythrocytes showed reasonable entrapment efficiency of 42.07 ± 3.6% of drug loading [74]. La-
pointe et al. indicate that thermoresponsive materials such as poly (N-isopropylacrylamide) based
nanoparticles could be embedded in hydrogel and have a better application of drug delivery than
traditional method [75]. Chen et al studied in vitro skin permeation experiments for the measure-
ment of efficiency of drug-loaded nanoparticles delivery, particularly these nanoparticles having
average diameters of about 30 nm and 100 nm and their structure is composed of inner spHerical
solid spheres and an outer hydrogel matrix [76].
A breakthrough method for local drug release is fabricating in situ cross-link hybrid hydro-
gel composed of polysaccharides (hyaluronic acid, dextran and/or carboxymethyl cellulose) and
gelatin, showing the ability for releasing proteins with minimal cytotoxicity [77]. Another case
is in situ thermoreversible gel comprising liposome-containing paclitaxel is studied as controlled
release method and can improve the antitumor drug efficiency [78].
1.3 Research Objectives
From the above literature review, it is known that the challenge for MI repair with tissue engineering
strategies is to supplement functional cells to the MI site, meanwhile keeping the cells alive and
functioning. To overcome this challenge, this thesis aims to develop injectable alginate hydrogels
for the controlled release of growth factors and the encapsulation of living cells. Two main specific
research objectives are set and outlined as below:
1.3.1 Co-delivery of BIO and IGF-1 in Nanoparticles by Hydrogel
Differentiation and proliferation of endogenous cardiomyocytes in situ can effectively improve car-
diac repair following myocardial infarction (MI). This objective is to perform a study on the sus-
tained co-delivery of BIO and IGF-1 in a hybrid hydrogel system to simulate endogenous cardiac
repair in an MI rat model. For this, both BIO and IGF-1 are to be encapsulated in gelatin nanoparti-
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cles, which are later cross-linked with the oxidized alginate to form a novel hybrid hydrogel system.
Then, in vitro and in vivo tests are to be performed so as to illustrate the effectiveness of the hybrid
hydrogel system for co-delivery BIO and IGF-1 to the MI area, in terms of the proliferation of
cardiomyocytes and revascularization.
1.3.2 Synthesize Alginate Hydrogels and Optimize Cell Viability
High cell retention rate, cell viability and the long term cell live/dead ratio after transplanting
living cells are important in MI repair. This is needed to supplement the functional cell in MI area
as an effective way for enhancing heart function. This objective is to fabricate injectable hydrogels
encapsulating living cells, which is easier to inject cells into the MI area with fewer trauma during
the surgery, then test and optimize the cells viability after injection by selecting the components of
the hydrogels. For this, the injectable alginate hydrogel of different compositions with two methods
briefly described as self-crosslinking hydrogel and cross-linker (Ca2+) adjusted hydrogel are to be
synthesized. The living stem cells are to be encapsulated into both types of hydrogels and the cells
viability and long-term live/dead ratio are to be examined.
1.4 Thesis Organization
This thesis is composed of four chapters. Chapter 1 gives the introduction and research objectives
of this thesis; Chapters 2 and 3 present the work related to the two research objectives; Chapter 4
discusses the conclusions drawn from this thesis as well as the future work.
Chapter 1 briefly introduces the background of myocardial infarction and presents the literature
review on tissue engineering treatments for MI repair; and on this basis, this chapter defines two
research objectives to be achieved.
In chapter 2, the first research objective and methods as well as results of the controlled release
of BIO and IGF-1 for MI repair in animal models have been described and discussed.
Briefly, a pH sensitive hybrid hydrogel system combining with nanoparticles for co-delivery of
BIO and IGF-1 for simulating endogenous cardiac repair in MI rat models was fabricated. Growth
factors BIO and IGF-1 were aimed to be efficiently encapsulated into gelatin nanoparticles, and
then these nanoparticles were cross-linked with the oxidized alginate hydrogel for forming a novel
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hybrid hydrogel system. With the change of pH value in the micro-envrionment after MI in re-
sponse of time growing, both growth factors were released for the specific concentration via dis-
connecting from the hydrogel. The release profile of the nanoparticles from the hydrogel and the
release of the small molecular growth factors from nanoparticles were described. Taken together
all in vivo results, it indicates that this hybrid hydrogel system have enhanced the proliferation of
cardiomyocytes and promoted the angiogenesis in the MI area, which further improved the cardiac
function.
In chapter 3, the research objectives and methods as well as experimental results of encapsulat-
ing living stem cells in alginate hydrogel for MI repair have been described and discussed.
Generally, two types of injectable alginate hydrogels based on self-crosslinking (SCL) and
calcium ion crosslinking (Ca2+) with various components were synthesized. Then living muscle
derived stem cells were encapsulated into both types of hydrogels, for their performance evaluation
in terms of optimizing cells viability during the injection process, and long term cells live/dead
ratio after two months cultivation. The characters of both types of hydrogels and the behaviour
of living cells were studied. By comparing the cells viability and long term cells live/dead ratio
in both types of hydrogels in varying formulations, the appropriate composition of hydrogel was
selected. Overall, the SCL hydrogel with a 0.8% alginate and 20% gelatin has the highest cells
viability during the injection process and the Ca2+ hydrogel with a 1.1% alginate and 20% gelatin
has the highest cells live/dead ratio after two months of cultivation.
In chapter 4, the conclusions based on the research objectives and obtained results were sum-
marized and future work has been described.
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2 Sustained Co-delivery of BIO and IGF-1 by a Novel
Hybrid Hydrogel System to Stimulate Endogenous
Cardiac Repair in Myocardial Infarcted Rat Hearts
Notes: Sections 2.1 – 2.6 of this chapter are adopted from the publication of “Fang, R.; Qiao,
S.; Liu, Y.; Meng, Q.; Chen, X.; Song, B.; Hou, X.; Tian, W. Sustained Co-Delivery of BIO and
IGF-1 by a Novel Hybrid Hydrogel System to Stimulate Endogenous Cardiac Repair in Myocar-
dial Infarcted Rat Hearts. Int. J. Nanomed. 2015, 10, 4691–4703. According to the Copyright
Agreement, "the authors retain the right to include the journal article, in full or in part, in a thesis
or dissertation".
Author contributions
Rui Fang performed the majority of the research and wrote the paper. Shupei Qiao helped revise
the paper. Yi Liu, Qingyuan Meng, Bing Song and Xiaolu Hou helped with in vivo tests and
measurements. Weiming Tian and Xiongbiao Chen supervised the research and revised the paper.
2.1 Abstract
Dedifferentiation and proliferation of endogenous cardiomyocytes in situ can effectively improve
cardiac repair following myocardial infarction (MI). 6-Bromoindirubin-3-oxim (BIO) and insulin-
like growth factor (IGF)-1 are two potent factors that promote cardiomyocyte survival and pro-
liferation. However, their deliveries for sustained release in MI-affected areas was proven to be
challenging. In the current paper, we present a study on the sustained co-delivery of BIO and
IGF-1 in a hybrid hydrogel system to simulate endogenous cardiac repair in a MI rat model. Both
BIO and IGF-1 were efficiently encapsulated in gelatin nanoparticles, which were later cross-linked
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with the oxidized alginate to form a novel hybrid hydrogel system. The in vivo results indicated
that the hybrid system could enhance the proliferation of cardiomyocytes in situ and could promote
revascularization around the MI sites, allowing improved cardiac function. Taken together, we con-
cluded that the hybrid hydrogel system can co-deliver BIO and IGF-1 to areas of MI and improve
cardiac function by promoting the proliferation of cardiomyocytes and revascularization.
2.2 Introduction
Many heart diseases primarily result in the loss of cardiomyocytes. It has been a significant chal-
lenge to develop effective treatments for cardiac repair because adult mammalian cardiomyocytes
are highly differentiated cells and have long been thought to undergo terminal differentiation [79].
Contrary to this long-held view, an emerging strategy posits that in response to heart injury, resi-
dent cardiomyocytes and cardiac stem cells surrounding the injured area can migrate and rapidly
re-enter the cell cycle, thus promoting heart function recovery [80, 81]. However, the endogenous
regenerative capacity of hearts is limited due to the massive loss of cardiomyocytes after myocar-
dial infarction (MI) and heart failure. MI is considered a major cardiovascular disease, and it was
found to be a major factor that contributed to non-natural mortality worldwide in 2013 [82, 83].
Current stem cell-based therapies have the potential to fundamentally improve the treatments of
ischemic cardiac injury and heart failure. These therapeutic approaches mainly involve the use
of bone marrow-derived mononuclear cells and their subsets, such as mesenchymal stem/stromal
cells, endothelial progenitor cells, as well as adipose tissue-derived muscle stem cells, cardiac
tissue-derived stem cells, and cell combinations [84, 85, 86, 87]. However, these stem cell therapies
have low efficacy due to poor cell engraftment and differentiation under the harsh (low nutrient and
low oxygen) ischemic environment of infarcted hearts [84, 85]. Previous studies have shown that
fewer than 2% of cells survive a few weeks after the stem cells’ delivery [86, 87, 88]. Despite the
availability of many treatment options, heart disease remains the leading cause of death worldwide,
raising the great need for novel or innovative therapeutic strategies. A recent study on stimulat-
ing cardiomyocyte dedifferentiation and proliferation by activating the mitotic signaling pathways
involved in embryonic heart growth represents a complementary approach for heart regeneration
and repair [89, 90, 91, 92]. An inhibitor of glycogen synthase kinase-3,6-Bromoindirubin-3-oxim
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(BIO), which is isolated from mollusk Tyrian purple indirubins, has been shown able to induce
the dedifferentiation of cardiomyocytes or endothelial cells, thus promoting mature cardiomyocyte
proliferation [93, 94]. On the other hand, substantial data also illustrate that insulin-like growth fac-
tor 1 (IGF-1) is a potent cardiomyocyte growth and survival factor. It has been illustrated that IGF-1
deletion has harmful effects on cardiac growth and its deficiency is associated with an increased
risk of cardiovascular disease [95, 96]. Cardiac-specific overexpression of IGF-1 can protect against
myocyte apoptosis and ventricular dilation following MI [97, 98]. Recently, drug delivery systems
using biomaterials as vehicles have drawn considerable attention. Studies have shown that by com-
bining growth factors with an injectable biomaterial, the biomaterial could serve as a controlled
drug-release platform to improve functional outcomes [99, 100]. However, co-delivery of BIO and
IGF-1 to the injured heart area remains a challenge. Daily injections of both BIO and IGF-1 is a
straightforward method that can maintain these agents at appropriate levels; however, this method
causes issues, such as toxicity, due to their high doses [101]. In the current research, we report
a novel hybrid hydrogel system of chemically encapsulated gelatin nanoparticles (NPs) for the
sustained co-delivery of BIO and IGF-1 in MI treatment.
2.3 Materials and Methods
2.3.1 Materials
Alginate (low viscosity), gelatin, sodium periodate, and hydrochloric acid were purchased from
Sigma Aldrich Co. (St. Louis, MO, USA); BIO was purchased from EMD Millipore, a division
of Merck KGaA (Darmstadt, Germany); IGF-1 was supplied by ProSpec-Tany TechnoGene Ltd
(Rehovot, Israel); and Cy7 (molecular formula: C35H41KN2O8S2) was purchased from Fanbo Bio-
chemicals Co (Beijing, People’s Republic of China).
Sprague-Dawley (SD) male rats, specific pathogen free (SPF) (weighting 200-250g each), pro-
vided by the Laboratory Animal Center of Harbin Medical University (Harbin, People’s Republic
of China), were used to isolate cardiomyocytes, and served as MI animal models. All animals were
fed ad libitum and kept under the normal 12-hour dark/12-hour light cycle. All procedures were




Blank gelatin NPs (BgNPs) were prepared using a two-step desolvation method with slight modifi-
cations [102, 103]. Briefly, gelatin was dissolved at 5 wt% in distilled water by stirring at 55 ◦C for
2 hours. Then, the pH of the gelatin solution was adjusted to proceed with the second desolvation
step. To prepare the BIO-loaded gelatin NPs (OgNPs), IGF-1-loaded gelatin NPs (FgNPs), and
BIO-IGF1 co-loaded gelatin NPs (CgNPs), 10 µL of 5 µM BIO (dissolved in 500 µL of dimethyl
sulfoxide [DMSO]) and 10 µL of 10 µM IGF-1 were added individually or together into 10 mL of
5% gelatin solution in a dark environment respectively, followed by the dropwise addition of ace-
tone (30 µL) to form NPs. At the end of the process, a glutaraldehyde solution (25% v/v aqueous
solution) was added as a cross-linking agent and the solution was stirred for 12 hours at a speed of
600 rpm. DMSO was removed by means of distilled water. Eventually, the solution was centrifuged
at 12,000 rpm for 1.5 hours, yielding the NPs. Dynamic light scattering was conducted using a Ze-
tasizer Nano ZS system (Malvern Instruments, Malvern, UK) to characterize the distribution and
size of the NPs.
Encapsulation Efficiencies of NPs
The encapsulation efficiency of the BIO and IGF-1 within the NPs was evaluated using an ultravi-
olet (UV) method. A drug-encapsulating gelatin NP solution was filtered through a Millipore filter
(UFP2THK24 [100 kD cutoff]), where the free drug present in the aqueous buffer passed through
the filter, leaving the drug entrapped in the NPs. Following the separation of the NPs from the
aqueous buffer, the drug left in the aqueous buffer was measured using a 752 UV/visible recording
spectrophotometer with a wavelength of 500 nm and 280 nm respectively. The total amount of drug
left in the aqueous solution was subtracted from the amount of drug originally added in the reaction
medium, and the entrapment efficiency (E %) was calculated from the ratio of the amount of drug
entrapped over the total amount of drug added.
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Synthesis of Self-cross-linked Hydrogel and Its Physicochemical Characterization
Hydrogel was synthesized as previously described [104]. Briefly, oxidized alginate was obtained
by mixing sodium peroxide and sodium alginate (in distilled water) with mass ratios of 1:2. The
reaction was conducted at 4 ◦C overnight and the degree of oxidation was evaluated by measuring
the concentration of sodium peroxide. Sodium peroxide was left unconsumed after 24 hours and the
concentration was measured by titration of hydrochloric acid (0.5 wt%). The oxidized alginate and
gelatin hydrogel were then obtained by mixing the alginate dialdehyde and gelatin NP solutions.
The gelation process and the mechanical properties of oxidized alginate and gelatin hydrogel were
evaluated by examining the time of gelation onset and the evolution of elasticity at 37 ◦C in the
constant strain mode by means of a Bohlin Gemini II rheometer (Malvern Instruments) featuring a
parallel plate geometry (40 mm in diameter), as in our previous study [104].
Drug-releasing Profile in vitro and in vivo
To monitor the in vitro release profile, gelatin NPs and each of the encapsulating drugs were made
to conform by means of a semi-permeable membrane (40 KD) and were then immersed in 10mL
of phosphate buffered saline at 4 ◦C for release within a time period of 7 days; every 24 hours, the
optical density was examined by a UV spectrophotometer at 500 nm. A sample of 1 cm3 of the
encapsulating drug (10 uL) was examined under the same conditions as the control group, so as to
study the drug’s release profile. To monitor the in vivo release profile, an in vivo imaging method
was used. First, the gelatin NPs were labeled with the fluorescent agent Cy7, and then the labeled
gelatin NPs were conjugated to the hydrogel, as described in section 2.3.2. Both the labeled gelatin
NPs alone, as well as the labeled gelatin NPs that conjugated to the hydrogels, were injected into
the area affected by MI in 20 rats (10 rats in each group), as described in a previous study [104].
The fluorescence of both groups was examined and recorded by an in vivo imaging system (DXS
4000 PRO; Eastman Kodak Co, Rochester, NY, USA) every 5 days.
Cardiomyocyte Culture
Neonatal cardiomyocytes were isolated from 2- to 3-day-old SD rats, as adapted from a previ-
ous protocol [105]. Hearts were removed from the neonatal rats; then, atrial and connective tissues
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were excised. Hearts were minced into 1mm3 pieces and then subjected to five rounds of enzymatic
digestion for 8–10 minutes with collagenase II (0.5mgmL−1; Worthington Biochemical Corpora-
tion, Lakewood, NJ, USA). Digestion was stopped with an equal volume of Dulbecco’s Modified
Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS) (Thermo Fisher Scientific,
Waltham, MA, USA). The cell suspension was centrifuged for 5 minutes at 2,000 xg and the result-
ing pellet was resuspended in DMEM containing 10% FBS. Cells were pre-plated in cell culture
flasks to reduce non-myocyte contamination (Corning Incorporated, Corning, NY, USA) for 90
minutes. Isolated cardiomyocytes were made into a suspension using oxidized alginate conjugated
with gelatin NPs at a density of 105 cells/mL. The obtained cells suspension are a mixture of car-
diomyocytes and fibroblasts. Since cardiomyocytes could be stained by anti-sarcomeric antibody
via immunofluorescence, the purity of the cardiomyocyte suspension can be evaluated by counting
the numbers of anti-sarcomeric antibody positive cells or by visual inspection.
Cell Proliferation in Hydrogels Assay
After 7 days of culture, the hydrogel/cardiomyocyte constructs were fixed. Immunofluorescence
was performed with the proliferating cell nuclear antigen (PCNA) antibody (1:200; Abcam plc,
Cambridge, UK) to identify the proliferation of cardiomyocytes. Laser confocal images were ob-
served and the PCNA-positive cells were counted.
MI Animal Model Preparation and Hydrogel Implantation
Ninety-five male SD rats (weighting 250 g each) were operated on to create the MI animal mod-
els. The rats were anaesthetized with an intravenous injection of 3% pentobarbital sodium (
30mg kg−1) [106], and an MI was subsequently induced ligating the left anterior descending coro-
nary artery 2mm from the top of the normally-positioned left auricle. Rats could be died because
of surgery and severe induced MI. We waited for 7 days to make sure there are no rats died be-
cause of the above reasons. Otherwise, we have to occlude there rats from the final experimental
analysis. One week later, each rat was injected with 80 µL of a given hydrogel (Table 2.1) into the
anterior and lateral regions bordering the infarct, as well as at the center of the infarct (16 uL per re-
gion). Anaesthetic operation with the same dosage was performed on the rats before the ultrasound
evaluation and hydrogel injection.
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Table 2.1: Groups and number of animals used for in vivo MI repair. Abbreviations: MI,
myocardial infarction; BIO, 6-bromoindirubin-3-oxime; IgF-1, insulin-like growth factor 1.
Sham animals accidentally died because of the surgery.
Groups # of animals per group # of animals survived at 6
weeks post-surgery
Survival rate
Sham 15 12 0.80
Control 20 11 0.55
IGF-1 20 14 0.70
BIO 20 17 0.85
BIO and IGF-1 20 16 0.80
Histology and immunohistochemistry
At 6 weeks post-implantation, the rats were anesthetized by 3% pentobarbital sodium (30 mg kg−1)
and then arrested with 10% KCl, rapidly excised, and frozen in tissue medium, which was followed
by sectioning each heart into three or four transverse slices parallel to the atrioventricular ring. Sam-
ples were then fixed with 10% buffered formalin, embedded in paraffin, sectioned into 5 µm slices,
and stained with hematoxylin and eosin (H&E). Scar thickness was measured under a microscope,
and on this basis, the relative scar thickness (defined by the average scar thickness divided by the
average wall thickness) and the heart expansion index (defined by the LV cavity area/whole LV
area/relative scar thickness) were evaluated, as in our previous study [104]. The detection of vari-
ous tissue antigens was conducted using the primary antibody, CD31, for endothelial cells (Abcam
plc). Double staining with anti-cardiac troponin-T (green, cardiomyocyte marker; Abcam plc) and
anti-PCNA (red, proliferation marker; Abcam plc) was performed. The doubled-stained cells were
evaluated by counting the average number of positively stained cells within six areas of 0.1mm2.




All of the results were reported as the mean ± standard deviation. Two-way analysis of variance
(ANOVA) was used in the analysis of heart function between groups. One factor is the revascu-
larization and the other is cardiomyocytes regeneration. Post hoc Student’s t-test was used for the
remainder of the analysis to identify which particular differences between pairs of means are signif-
icant. A P-value <0.05 (*) was considered significant; a P-value <0.01 (**) was very significant.
2.4 Results
2.4.1 Preparation and Characterization of Hydrogels and the Drug-release
Profile in vitro and in vivo
Figure 2.1: Release assay profile in vitro. Notes: (A) SEM morphology of the prepared
gelatin NPs. (B) Dynamic light scattering (DLS) analysis of the gelatin NPs. (C) SEM image
and a zoomed image showing the gelatin NPs covalently conjugated to the hydrogel. (D) The
UV results of BIO absorption showing the release profiles in the free NP group and in the
gelatin NP encapsulated in hydrogel group. (E) Mechanical properties of the hydrogel before
and after release. Abbreviations: SEM, scanning electron microscope; DLS, dynamic light
scattering; BIO, 6-bromoindirubin-3-oxime; NP, nanoparticle; UV, ultraviolet.
The morphology of BgNPs was observed using a scanning electron microscope (SEM) (Fig-
ure 2.1 A); the results of dynamic light scattering showed that the NPs formed a cluster featur-
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ing different diameters ranging from 180 nm to 255 nm with a polydispersity index (PDI) of
0.158 ± 0.029 (Figure 2.1B). Then, the NPs were covalently attached to the hydrogel, as we had
previously reported [102]. The hydrogel formed with the porous network structure (Figure 2.1C).
The loading efficiency of OgNPs and FgNPs, which contained BIO and IGF-1, respectively, were
about 55% or 60%, which is similar to the findings of a previous study [107]. To detect the re-
lease profile of the NPs and the hydrogel composite system, we designed a method to examine the
BIO release profile in the NPs conjugated to the hydrogel and in the free NPs, as described in the
encapsulation efficiencies of NPs section. We compared the release behaviour of BIO in NPs and
in NPs covalently conjugated to the hydrogel. The release profile assay lasted for 110 hours for
both groups. The release rate of BIO in NPs was much higher than that the release rate of BIO
in NPs encapsulated in hydrogel (Figure 2.1D). From 0 to 60 hours, a rapid increase in the drug
release was observed in the NPs; however, a similar release peak was detected from 60–90 hours in
the NPs conjugated to the hydrogel (Figure 2.1D). For NPs, the BIO release mechanisms included
the biodegradation of NPs; in addition, BIO diffuses to the solution outside the semi-permeable
membrane.
In contrast with NPs, two steps were involved in the BIO’s release profile in NPs covalently
conjugated to the hydrogel. The first step involves the breakage of amines found between the NPs
and the hydrogel, and the second step includes BIO’s release from the NPs. As a result, the peak
release was postponed 60 hours in the in vitro delivery system. To further confirm the release
mechanism of NPs, the mechanical properties of the hydrogel were measured and compared to its
original properties prior to being released. The results showed that the elastic and viscous moduli
of the hydrogel were around 105 and 104 Pa prior to release, respectively, and they had decreased
to 103 and 10 Pa, respectively, after release (Figure 2.1E).
However, there was a tendency where the elastic and viscous moduli to stay the same before and
after the release, which indicated that the hydrogel still maintained a gel network structure. There-
fore, we postulated that the main releasing mechanism occurs through the breakage of chemical
bonds between gelatin NPs and oxide alginate–gelatin hydrogel. The release profile was also con-
trolled by the cross-linking density and degradability of the gel, modulated by the initial gelation
condition. The in vivo release profile was evaluated using the in vivo imaging method, as shown in
Figure 2.2 A. The results illustrated that the fluorescence of the scaffold encapsulating Cy7-labeled
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Figure 2.2: In vivo release profile assay. Notes: (A) The scheme showing the strategy used
to monitor the release profile using an in vivo imaging method. (B) Typical images of rats
implanted with free Cy7-labeled NPs and Cy7-labeled gelatin NPs encapsulated in hydrogel.
(C) The statistical analysis of immunofluorescence intensity remained constant over time
(n6). Abbreviation: NP, nanoparticle.
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NPs could last for 45 days, while the fluorescence of the control group (free Cy7-labeled NPs,
which were not conjugated to the hydrogel) lasted for less than 10 days (Figures 2.2 B and 2.2
C). Moreover, the intensities of the fluorescence were much higher than those in the control group
(Figure 2.2 C).
2.4.2 Cardiomyocyte Proliferation Detected in Hydrogels
To mimic the in vivo effect of the drug delivery system among cardiac cells, a three-dimensional
(3D) system was used to encapsulate the cardiomyocytes in hydrogel in the present study. The
results showed that the percentage of proliferated cardiomyocytes in the BIO release system (15%±
4%) was significantly higher than that in the control groups (7% ± 3%; P < 0.05); however, no
significant difference was observed in the IGF-1 release group (11%± 2%), as shown by the laser
confocal images (Figures 2.3 A, 2.3 B, and 2.3 C) and the statistical analyses (Figure 2.3 D).
Therefore, IGF-1 could not induce the proliferation of cardiomyocytes.
2.4.3 BIO/IGF-1 Administration Improves Cardiac Function after MI and
Leads to the Formation of New Cardiomyocytes
MI animal models were prepared according to the method described above, and different hydro-
gels that covalently conjugated with various NPs (blank gelatin NPs, OgNPs, FgNPs, and CgNPs)
were implanted to detect their effects on cardiac function repair. Even though IGF-1 by itself was
ineffective in promoting cardiomyocyte proliferation in a culture system, there might be integrated
impact between BIO and IGF-1 for MI repair.
In order to study the mechanism underlying the advancement of cardiac function for the ad-
ministration of BIO + IGF-1 in the MI rats, H&E staining was used perform a histology evaluation
following injection with our hydrogel system. Cardiac remodeling was found in our experimental
groups; however, through visual inspection, when compared to the control group, more cardiomy-
ocytes can be found visually in the BIO + IGF group as shown in Figure 2.4. Note that even though
fibrosis can be observed in the slides, it is commonly not used as an evaluation factor in this type
of research. The results were further confirmed by double staining with the anti-cardiac troponin-T
(green; cardiomyocyte marker) and anti-PCNA (red; proliferation marker) assay. The number of
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Figure 2.3: Effect of the hydrogel delivery system on the proliferation of 3D culture car-
diomyocytes. Notes: Scheme showing the strategy used to detect the enhanced proliferation
of 3D-cultured cardiomyocytes. Laser confocal images showing the PCNA-positive stained
cells in the (A) BgNP group, (B) FgNP group, and (C) OgNP group. (D) Statistical analysis
(t-test) of the number of PCNA-positive cells (n=6). **P = 0.01 OgNPs versus the BgNP
group. Abbreviations: BIO, 6-bromoindirubin-3-oxime; 3D, three dimensional; PCNA, pro-
liferating cell nuclear antigen; NP, nanoparticle; BgNP, blank gelatin nanoparticle; OgNP,
BIO-loaded gelatin nanoparticle; IGF-1, insulin-like growth factor 1; FgNP, IGF-1-loaded
gelatin nanoparticle.
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Figure 2.4: Histology evaluation of an ischemic heart. More cardiomyocytes can be found
visually in (E) as compared to the others. Notes: (A–E) H&E staining of the tissue sections
obtained from the MI region among the (A) sham group, (B) control group, (C) IGF-1 release
group, (D) BIO release group, and (E) BIO and IGF-1 co-delivery group. Scale bar, 100um.
Abbreviations: BIO, 6-bromoindirubin-3-oxime; IGF-1, insulin-like growth factor 1; H&E,
hematoxylin and eosin; MI, myocardial infarction.
proliferating cardiomyocytes in the BIO + IGF-1 group (35 ± 5) was the most significant among
all groups, and the number of proliferating cardiomyocytes in the BIO group (27 ± 5) was also
significantly higher than that of both the sham (5± 2) and the control groups (15± 5) as shown in
Figure 2.5. In the BIO delivery group, the enhanced proliferation of cardiomyocytes was observed.
In the co-delivery of BIO + IGF-1 group, both enhanced proliferation of the cardiomyocytes and
function recovery were seen. Moreover, angiogenesis plays a crucial role in tissue repair and heart
function after MI; therefore, the CD31 antibody-positive angiogenesis assay was detected among
the different groups as shown in Figure 2.6. In the BIO+ IGF -1 group, the most capillaries (70±8/
mm2) was observed. In addition, significant increase of blood vessels (60 ± 7/mm2) in the IGF-1
group was also detected. However, no significant increase in blood vessel density was observed in
the BIO group (43±8/mm2), which suggested that BIO could not promote angiogenesis. Enhanced
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angiogenesis was accompanied by functional recovery in the BIO and IGF-1 group; this indicates
that angiogenesis may be an important factor in the recovery of function.
Figure 2.5: Double staining with anticardiac troponin-T (green; cardiomyocyte marker)
and anti-PCNA (red; proliferation marker) shows the enhanced proliferation of resident car-
diomyocytes in an MI model (P< 0.01; n=6). Notes: (A) Sham group, (B) control group,
(C) IGF-1 release group, (D) BIO release group, and (E) BIO and IGF-1 co-delivery group.
(F) Statistical analysis of the number of double-stained cells. **P < 0.01 versus the control
group. The arrows show the cardiomyocytes which are double staining. Abbreviations: BIO,
6-bromoindirubin-3-oxime; IGF-1, insulin-like growth factor 1; MI, myocardial infarction;
PCNA, proliferating cell nuclear antigen.
2.5 Discussion
In the present study, we investigated the functional and histological/cellular effects of the intramy-
ocardial administration of BIO and IGF-1 in MI rats. We showed that the improved sustained
co-delivery of BIO and IGF-1 by a newly developed hybrid hydrogel system holds potential as a
novel treatment for MI. Six weeks after delivery, BIO and IGF-1 treatment led to the proliferation
of resident cardiac cells and promoted revascularization. Importantly, the repair and regeneration of
the damaged myocardial tissues was associated with significant improvements in cardiac function
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Figure 2.6: Immunostaining for the evaluation of angiogenesis. Notes: (A–D) CD31 im-
munostaining of the tissue sections from the MI among the (A) sham group, (B) control
group, (C) BIO release group, (D) IGF-1 release group, and (E) BIO and IGF-1 co-delivery
group. (F) Statistical analysis of the CD31-positive blood vessels (n = 6). *P < 0.05
versus the control group; **P < 0.01 versus the control group. Abbreviations: BIO, 6-
bromoindirubin-3-oxime; IGF-1, insulin-like growth factor 1; MI, myocardial infarction.
as shown in Figure 2.7.
2.5.1 Development of a New Hybrid Hydrogel System
Recently, studies have reported on the ways in which cardiac diseases can be treated through the
sustained delivery of IGF-1 by means of hydrogels [108, 109]. Though it makes a difference in
the treatment of MI, IGF-1 also causes such issues as toxicity due to their high doses and the short
release profile. Gelatin NPs, due to their good biocompatibility and biodegradability, have been
widely utilized in drug delivery applications [110]. However; the relatively fast degradation of
gelatin limits its applications to long-term protein delivery. Our previous study showed that the
covalent cross-linking of gelatin with alginate forms a hydrogel with both enhanced mechanical
properties and bioactive motifs for cell attachment, biodegradability, and functional recovery [104].
23
Figure 2.7: Scheme showing the mechanism of BIO release within the hydrogel after injec-
tion into the MI area. Abbreviations: BIO, 6-bromoindirubin-3-oxime; IGF-1, insulin-like
growth factor 1; MI, myocardial infarction.
In the current study, we developed a novel hybrid hydrogel system with chemically encapsulated
gelatin NPs, which are pH sensitive, for the sustained co-delivery of BIO + IGF-1 in MI treatment.
The oxidation of sodium alginate produced aldehyde groups, which can form unstable amines
found within the free amino group in the gelatin NPs; thus, they covalently linked the NPs to the
alginate polymer chain. An acidic, low pH environment was generated with the occurrence of an
MI [83]. The amines that were found, which form between alginate and the gelatin NPs, are most
active in acidic environments. Following MI, the bond broke down quickly and the BIO and IGF-1
were released to the damaged area of the heart, ultimately promoting the heart’s overall function.
In summary, in our study, we developed a novel, pH-sensitive, hybrid hydrogel system of chem-
ically encapsulated gelatin NPs that can more efficiently sustain the co-delivery of BIO and IGF-1
to the injured area of the heart. Further, we also illustrated that the system could be more advanta-
geous when delivering BIO and IGF-1 in the treatment of MI.
2.5.2 Sustained Release of BIO or IGF-1 using Hybrid Hydrogel Systems
Drug release profiles were detected both in vitro and in vivo. It is generally recognized that 2D cell
cultures are not adequate representatives of the cellular environment found in organisms; rather,
3D cell culture models have the potential to improve the physiological relevance of cell-based
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assays [111]. In our previous study, we constructed an engineered heart tissue model using car-
diomyocytes [104]. In order to mimic the in vivo effect of a drug delivery system when promoting
the proliferation of cardiac cells, a 3D system to encapsulate the cardiomyocytes in the hydrogels
was used in the present study. The drug-release rate was detected in vivo by an imaging system that
has been widely used in cancer studies. More recently, a study showed that it can also be used to
evaluate biomaterial biodegradation in vivo [112]. Cy7 was conjugated to the NPs, and the rapidly
decreasing fluorescence intensities in the NP group indicated that without the support of the sub-
strate, the NPs diffused quickly following injection into the infarcted area. Also, it was found that
the fluorescence intensities decreased quickly at first, and then they slowly continued to decrease
with the treatment of MI via the injection of hydrogels; this result may be due to the fact that our
system is pH sensitive. Our results on the elastic and viscous moduli of the hydrogel illustrate
that there is not much difference prior to and after release, which indicates that the hydrogel still
maintains a gel network structure. As such, the controlled release profile was mainly caused by the
breakdown of the chemical bond between NPs and hydrogel, rather than by the drug itself.
2.5.3 Heart Regeneration with Our Novel Hybrid Hydrogel System of Chem-
ically Encapsulated Gelatin NPs
With the development of intramyocardial biomaterial, more and more biomaterials are being used
for injection therapy [108]. To date, it has already been demonstrated that many small molecules
contribute to heart regeneration; however, the mechanisms by which these benefits are obtained
remain unclear [113]. Here, we show that following BIO administration, the number of resident
cardiac cells in an MI model increased. Our findings further indicate that the function of BIO can
promote dedifferentiation and proliferation in terminally differentiated cardiomyocytes in vivo. The
BIO could reprogram the cardiomyocytes with changed morphology evidenced through rearrange-
ment of the cytoskeleton [93], which can be clearly observed in the anticardiac troponin-T staining
in Figure 2.5. In a recent study by Kohler, it was demonstrated that low doses of BIO also have the
ability to induce partial dedifferentiation among endothelial cells by regulating the canonical Wnt
pathway [114]. A previous study has shown that there is a dual role for BIO, which involves the
maintenance of stem cell properties and the induction of proliferation in differentiated cardiomy-
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ocytes; this indicates that these functions may share common molecular pathways that control the
canonical Wnt pathway [93, 115]. Secondly, our present findings document that IGF-1 can induce
angiogenesis following MI. Consistent with our study, a previous study showed that the local deliv-
ery of the IGF-1 gene by recombinant adeno-associated virus in the setting of acute MI resulted in
sustained IGF-1 expression, increased angiogenesis, and improved cardiac function [116]. Another
study also showed that IGF-1 enhanced wound healing and induced angiogenesis via a vascular
endothelial growth factor (VEGF)-independent pathway [117]. A previous study showed that im-
mobilizing IGF-1 with hydrogel could serve as a controlled drug-release platform, and that it could
also enhance cardiac progenitor cell survival and differentiation. In a study on chronically infarcted
pig hearts, IGF-1 and hepatocyte growth factor therapy also resulted in improved cardiac function
when using hydrogels [109]. In our current research, we developed a novel hybrid hydrogel sys-
tem with chemically encapsulated gelatin NPs for the sustained co-delivery of BIO and IGF-1 in
MI treatment. To our knowledge, this is the first report that remedies MI via the co-delivery BIO
and IGF-1, which have been identified as potential candidates to guide postnatal stem progenitor
cells toward a cardiomyogenic fate. In the present study, we demonstrated that the co-delivery of
BIO and IGF-1 can promote resident cardiomyocyte proliferation and revascularization. Therefore,
both BIO and IGF-1 can be involved potentially in contributing to the heart’s functional recovery.
As such, the entire study protocol employed in this present work is clinically feasible and may be
performed in a conventional catheterization laboratory.
2.5.4 Limitations
The concentrations of BIO and IGF-1 that were used in this work were adopted and used as per
previous studies [93, 100]. In the present study, the co-delivery of these two agents promoted the
function and regeneration of the heart following MI. However, it is not clear if the optimal concen-
tration of the co-delivery of BIO and IGF-1 can play an even more significant role in improving
heart function after MI, which would be interesting to pursue in the future. In addition, although
experimental work on the in vivo drug release of NPs encapsulated in hydrogel showed a 45-day
release for Cy7, we can not detect the release efficiency of BIO and IGF-1 directly. It would be
interesting to observe the delivery of these drugs over a longer period of time. This line of inquiry
also suggests that more non-invasive methods should be developed for drug tracing in the future.
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In section 2.4.3, the weight of the heart relative to body weight at the time of euthanasia was
not measured and this should be incorporated in the future experiments.
2.6 Conclusions
A novel hydrogel delivery system was developed to deliver drugs specifically to the site of an MI to
selectively enhance the proliferation of resident cardiac cells, resulting in enhanced heart function
recovery. Our results showed that NPs covalently entrapped in hydrogel hold great promise for
treating MIs and other related diseases given their ability to deliver a wide range of therapeutics.
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3 Synthesis of Injectable Alginate Hydrogels with
Muscle-Derived Stem Cells for Potential Myocardial
Infarction Repair
This chapter has been published as “Fang, Rui, Weiming Tian, and Xiongbiao Chen. “Synthesis
of injectable alginate hydrogels with muscle-derived stem cells for potential myocardial infarction
repair." Applied Sciences 7.3 (2017): 252." According to the Copyright Agreement, “the authors
retain the right to include the journal article, in full or in part, in a thesis or dissertation."
3.1 Abstract
Myocardial infarction (MI), caused by the occlusion of the left ventricular coronary artery, leads
to the loss of cardiomyocytes and, potentially, heart failure. Cardiomyocytes in adult mammals
proliferate at an extremely low rate and thus, a major challenge in MI treatment is supplement-
ing exogenous cells and keeping them viable in MI areas. To address this challenge, injecting
hydrogels encapsulating cells into MI areas, to compensate for the loss of cardiomyocytes, shows
promise. This study synthesized two types of alginate hydrogels, based on self-crosslinking (SCL)
and calcium ion crosslinking (Ca2+) in varying formulations. The hydrogels encapsulated living
muscle-derived stem cells (MDSCs) and their performance was evaluated in terms of optimizing
cell viability during the injection process, as well as the live/dead cell rate after long-term cultiva-
tion. The morphology of the hydrogel-encapsulated cells was characterized by scanning electronic
microscopy (SEM) and live/dead cells were examined using an MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide staining) assay. The mechanical properties of the hydrogels were
also determined via a rheometer, to identify their influence on cell viability during the injection
process and with respect to long-term cultivation. The SCL hydrogel with a 0.8% alginate and 20%
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gelatin formulation resulted in the highest cell viability during the injection process, and the Ca2+
hydrogel composed of 1.1% alginate and 20% gelatin maintained the highest cell survival rate after
two months in culture.
3.2 Introduction
Myocardial infarction (MI), commonly known as a heart attack, is caused by an interruption of the
blood supply to a part of the heart with cardiovascular disorder [118]. If left untreated, the ischemia
or resulting restriction in the blood supply may cause damage to the myocardium or cardiomyocyte
apoptosis, thus leading to heart failure. According to the latest statistics from the American Heart
Association [119], MI and other cardiovascular diseases are the leading causes of death worldwide.
The heart is primarily composed of the myocardium and coronary arteries. Supplied with oxygen-
and nutrient-rich blood through the coronary arteries, the myocardium continuously contracts and
relaxes, to pump blood throughout the body. The myocardium has an extremely limited regenera-
tion potential [120, 121], and so, after MI, the ischemic myocardium ceases to function properly,
due to the loss or death of cardiomyocytes, i.e., the cells of which it is comprised. Cardiomyoplasty
is a therapy used in MI repair, in which cardiomyoblasts or other types of stem cells are directly
injected into the injured heart, serving as renewable cellular sources which aid in the repair of
the damaged myocardium [122, 123]. To compensate for damaged or dead cardiomyocytes in the
MI area, the transplantation of various types of stem cells or exogenous cardiomyocytes has been
studied. Among them, cardiomyocytes [124, 125], embryonic stem cells [126, 127], and bone
marrow-derived mesenchymal stem cells [128] have been investigated, but the ideal cell type for
MI repair is far from certain [129]. Muscle-derived stem cells (MDSCs) are a promising type of
cell for MI repair because they have the ability to trans-differentiate into cardiomyocytes when co-
cultured with cardiomyocytes [130], resist oxidative stress-induced apoptosis [131] , reduce scar
formation [131, 132], and improve cardiac function [133, 134] after transplantation. Although car-
diomyoplasty is promising for MI repair, low cell viability after transplantation, and then gradually
decreasing cell survival after long-term cultivation, are issues that remain to be addressed. Encap-
sulating the cells to be transplanted into MI hearts in synthesized hydrogels may be an effective
way to improve the cell survival rate. Scaffolds or engineered constructs are important for tissue
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engineering [135], especially those with bioactive growth factors as a delivery system, which are
of great importance for cardiovascular tissue engineering [136]. The co-release of growth factors
of VEGF (vascular endothelial growth factor), bFGF (basic fibroblast growth factor), and PDGF
(platelet derived growth factor) from engineered constructs for cardiac repair after MI is promising
[137], but many conditions, such as the release rate, need to be regulated.
Hydrogels are cross-linked networks of polymers, such as fibrin and alginate, with a high water
content between polymer chains [138, 139]. When used for cell encapsulation, hydrogels provide
a hydrated tissue-like environment for cell attachment and protection, thereby improving cell vi-
ability. Hydrogels can provide biochemical cues and structural support, along with the possible
recruitment of endogenous stem cells [140]. Cellular growth and functions are critically affected
by both the cell compatibility of materials [141], and the pore sizes in the hydrogel structure
[142], which lead to varying cell viabilities. Combining injectable microspheres with a hydrogel is
an alternative approach [143]; however, research into cell therapies integrating microspheres and
hydrogels has been limited [144]. Among various injectable hydrogels, alginate cross-linked in the
presence of calcium ions has been drawing considerable attention for use in MI repair and can lead
to enhanced cell viability and proliferation, as well as an improved contractile function [145, 146].
Alginate, a biodegradable and biocompatible polysaccharide commonly found in algae, was em-
ployed in this study, due to its successful use as a hydrogel for tissue engineering [147, 148].
However, one inherent disadvantage of alginate is the lack of cell-surface receptors for cell attach-
ment, resulting from the negatively charged polymer. Considering this, we also used gelatin to
encourage cell adhesion, as it is the main component of the extracellular matrix (ECM) and can
promote cell attachment and migration [149, 150]. This research mainly focuses on optimizing (i)
cell viability during the injection process and (ii) the live/dead cell ratio after a period of cultivation
by optimizing the composition of alginate hydrogels encapsulating living MDSCs for potential MI
repair.
3.3 Materials and Methods
The preparation of materials for the experiments presented in this paper was carried out according
to protocols approved by the University of Saskatchewan Ethics and Integrity in Animal Research
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Committee (Saskatoon, Canada) and the Harbin Institute of Technology’s Animal Care (Harbin,
China) and Use Committee.
3.3.1 Materials
Sprague Dawley (SD) rats (m=400g, Laboratory Animal Center, Harbin Medical University, China),
Muscle derived stem cells (MDSCs, Bio-X center, Harbin Institute of Technology), Dulbecco’s
Modified Eagle Medium (Boster, Wuhan, China), 10% horse serum (Boster, Wuhan, China), sodium
alginate (low viscosity, Sigma, St. Louis, USA), semipermeable membrane (40 KDa, Sigma, St.
Louis, USA), MTT cell proliferation kit I (Sigma, St. Louis, USA).
3.3.2 Methods
Gelatin Extraction from Rat Tails
The gelatin used as a component of both hydrogels was obtained from the tails of Sprague Dawley
(SD) rats, following the same procedure as was presented in our previous work [151]. Briefly, three
male SD rats (400 g) were anaesthetized and collagen from their tails was extracted stick-by-stick,
via forceps. The collagen was dissolved in 0.5% glacial acetic acid (50 mL) at 4 ◦C for 72 h. Then,
the mixture (solution) of collagen and glacial acetic acid was sterilized by membrane filtration
(0.28 um) and finally freeze-dried to form a powder. The concentration of gelatin in this study was
determined by measuring the mass/volume ratio of the mass of collagen that dissolved completely
in the glacial acetic acid, to the volume of the solution. The gelatin powder was dissolved in sterile
phosphate buffer solution (PBS) to a concentration of 40%, for synthesizing the hydrogels in this
study.
Cell Cultivation
Using the same technique employed for 3D cell cultivation as in our previous work [146], MDSCs
were cultured in the two types of hydrogels described in sections 2.3 and 2.4. Briefly, MDSCs
were mixed evenly with alginate and then cross-linked with gelatin to form hydrogels. After the
crosslinking process, the cells were encapsulated in the hydrogels and then were cultured in Dul-
becco’s Modified Eagle Medium (DMEM, 10% horse serum added), which was refreshed daily.
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SCL Hydrogel Synthesis
SCL hydrogels were synthesized with partially oxidized sodium alginate cross-linking with gelatin,
following our previously published procedures [152]. Four hydrogel formulations, namely SCL
0.8%, SCL 1.1%, SCL 1.5%, and SCL 2%, based on their respective sodium alginate concentra-
tions, comprised four experimental groups. For each experimental group, sodium alginate (low
viscosity, Sigma, St. Louis, USA) was oxidized by sodium periodate at a concentration ratio of
2:1 for 8 h at 4 ◦C in the dark. The oxidation degree was measured via the mass of the remaining
sodium peroxide. Briefly the oxidization process was described as following: Sodium chloride
(0.5 g) and 100% ethanol (10 mL) were added to the oxidized alginate solutions, until sediments
formed. The sediments were then dissolved in deionized water (10 mL) and dialyzed for 72 h with
a semipermeable membrane (40 KDa, Sigma) at 4◦C ; thereafter, they were freeze dried into pow-
der and dissolved in sterile PBS to a concentration of 60%, and were then mixed with MDSCs to
a density of 0.5 x 105/mL. Sodium alginate solutions containing MDSCs were mixed with gelatin
at a 1:1 volume ratio and then printed through a 0.26 mm needle into hydrogels (beads). These
hydrogel-encapsulated cells were cultured in DMEM (refreshed daily) in a cell culture incubator
for two months.
Ca2+ Hydrogel Synthesis
Ca2+ hydrogels were synthesized via the physical crosslinking between calcium ions and alginate,
that is based on the attraction between positive and negative charges. Four hydrogel formulations,
namely Ca2+ 0.8%, Ca2+ 1.1%, Ca2+ 1.5%, and Ca2+ 2%, based on their respective concentrations
of alginate, were prepared and represented four experimental groups. For each experimental group,
MDSCs (0.5 x 105/mL) were mixed with sodium alginate solution and then with gelatin, at a 1:1
volume ratio. The mixture was dispensed through a 0.26 mm needle into 100 mM calcium chloride
solution (1% tween-20 added), in a tissue culture dish. Hydrogels (beads) encapsulating cells were
formed at the moment the mixture entered the calcium chloride solution. The calcium chloride
was then removed and the hydrogels were quickly rinsed with PBS. Cells were then cultured in the
same environment as outlined in section 2.3, for two months.
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SEM Examination of Hydrogel Morphology
The structure of the hydrogel-encapsulated MDSCs for each experimental group was examined via
scanning electron microscopy (SEM, Quanta 200, FEI, Hillsboro, USA). First, the hydrogels were
fixed in a solution containing 2% glutaraldehyde and 3% formaldehyde in cacodylate buffer (0.1 M
cacodylate, 0.09 M sucrose, 0.01 M MgCl2, and 0.01 M MgCl2, pH 6.9), for 1 h. They were then
dehydrated with a graded series of acetone (10%, 30%, 50%, 70%, 90%, and 100%) on ice, with
each lasting 15 min, followed by critical point drying with liquid CO2. Last, the hydrogels were
each cut into two hemispheres and attached to a conductive adhesive, then sputter coated with a
gold film to a thickness of 10 nm for observation via SEM (Quanta 200, FEI, Hillsboro, USA).
Mechanical Strength Measurement
The mechanical strength of both types of hydrogels was analyzed via rheometry, conducted at a
sweeping frequency ranging from 0.1 to 10 Hz. Hydrogels of a larger size were synthesized with
the same technique described in sections 2.3 and 2.4, via a pipette (1000 uL) in a six-well culture
dish. The hydrogels can form a lamella that fills up one whole well of the dish. Lamellas formed
from Kingdom), with a CP40 cone.
Hydrogel Degradation
Hydrogels were synthesized with an original weight of 0.8 g (SCL hydrogels) and 0.5 g (Ca2+
hydrogels) in each group (n = 6), and were then exposed to 0.5% collagenase type II (5 mL) at
body temperature, for 48 h. The hydrogels were then freeze-dried into powder for the weight
measurement. This process was repeated until all of the hydrogels had degraded (i.e., disappeared
completely).
MTT Assay for Cell Proliferation
The MDSCs encapsulated in all groups of both types of hydrogels were released by dissolution in
3% sodium citrate, after 2 h, 24 h, and two months of cell cultivation. Then, the survival rate of
these cells was measured by a MTT assay with the cell proliferation kit I (Sigma), immediately
after the cells were released from the hydrogels. Briefly, cells from each group were coated with
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MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide staining) for 4 h in 96-well
culture dish plates, until sediments formed; the control group was DMEM coated with MTT. The
three same wells for used for each group and each test was repeated six times. Then, with MTT
dissolvent was kept for another 4 h in the cell culture incubator. The optical density (OD) of the
resulting solution was determining using an ultraviolet spectrophotometer.
Fluorescent staining for Live/Dead Cells
MDSCs were released from the hydrogels of each experimental group via the method described in
section 2.8, after 2 h, 24 h, and two months of cultivation. They were then stained with calcein
(green) for 20 min and PI (red) for 5 min, to label live and dead cells, respectively. MDSCs were
also stained with DAPI, to mark the cell nuclei. The fluorescent staining in each layer of the
hydrogels was examined using confocal microscopy (FV3000, Olympus, Tokyo, Japan).
3.4 Results and Discussion
3.4.1 Morphology
The morphology via SEM is shown in Figure 3.1 , illustrating the texture and inner structure of the
SCL and Ca2+ hydrogels of all groups. Specifically, it shows the morphology of hydrogels without
cells: 1A for the SCL hydrogel and 1a for the Ca2+ hydrogel; and the morphology of hydrogels
with cells: 1B, 1C, 1D, and 1E SCL hydrogels, and 1b, 1c, 1d, and 1e for Ca2+ hydrogels, where
the alginate concentrations are 0.8%, 1.1%, 1.5%, and 2%, respectively. The SEM images show no
major differences in the inner structure of both SCL hydrogels and Ca2+ hydrogels, but reveal minor
differences between the two types of hydrogels in terms of pore size and degree of compactness.
Specifically, when studying the software image J, for the SCL and Ca2+ hydrogels, the average areas
of pore size were found to be 124 µm2 and 7.1 µm2, respectively, which indicates that the pore size
of the SCL hydrogels is significantly larger than that of the Ca2+ hydrogels; and the average number
of pores in each type of hydrogel per 125 µm2 area was six and 89, respectively, indicating the large
number of pores in Ca2+ hydrogels. When considering the pore density, calculated as the overall
area of pores (pore size multiplied by pores amount per 125 µm2) of each type of hydrogel, it was
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found to be slightly higher for the SCL hydrogels (744 µm2) than for the Ca2+ hydrogels (632 µm2).
The overall structure of the SCL hydrogels is a connective network, which contains fewer pores, but
of a larger size, than the Ca2+ hydrogels; while the Ca2+ hydrogels reveal a more compact network
structure.
With respect to the ability of the two types of hydrogels to entrap cells, the SEM images show
that the Ca2+ hydrogels, with their larger number of pores, appear better able to encapsulate cells
than the SCL hydrogels. Indeed, it was noted during the experimental process that large piles of
cells were easier to find in the Ca2+ hydrogels than in the SCL hydrogels. We attribute this to cells
in the Ca2+ hydrogels being able to survive and regenerate, due to proper growth signals secreted
from adjacent groups of cells; cells in Ca2+ hydrogels can build connections with each other more
easily, due to the shorter distance between them.
Figure 3.1: SEM images illustrating the morphology of SCL and Ca2+ hydrogels: Without
cells (A for SCL hydrogel and a for Ca2+ hydrogels) and with cells (B–E for SCL hydrogel
and b–e for Ca2+ hydrogels, both with varying concentrations of 0.8%, 1.1%, 1.5%, and 2%,
respectively).
3.4.2 Mechanical Strength
Four trendlines indicating the mechanical strength of the SCL hydrogels and Ca2+ hydrogels are
shown in Figure 3.2 A,B, respectively. Figure 3.2 A illustrates that the 2% SCL hydrogel had the
highest mechanical strength (0.57×104 Pa), followed by slightly lower strength in the 1.5% SCL
hydrogel (0.53×104 Pa), the considerably lower strength in the 1.1% SCL hydrogel (0.28×104
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Pa), and the lowest strength in the 0.8% SCL hydrogel (0.76×103 Pa). Figure 3.2 B shows that
Ca2+ hydrogels follow a similar trend in mechanical strength; the 2% Ca2+ hydrogel had the high-
est strength (0.23×105 Pa), followed by the 1.5%, 1.1%, and 0.8% Ca2+ hydrogels (at 0.216×105,
0.14×105, and 0.68×104 Pa, respectively). The mechanical strength results indicate that Ca2+ hy-
drogels are stronger than SCL hydrogels; the weakest Ca2+ hydrogel (0.8%) had a similar strength
to the strongest SCL hydrogel (2%).
Figure 3.2: Rheometry data with respect to the mechanical strength of the hydrogels. 0.8%,
1.1%, 1.5%, and 2% are the concentrations of alginate in both types of hydrogels, and the
varying concentrations of alginate present for the different groups of hydrogels. (A) The me-
chanical strength of SCL hydrogels with changing frequencies; (B) The mechanical strength
of Ca2+ hydrogels with changing frequencies.
3.4.3 Degradation
The rate at which the hydrogels degraded (in terms of weight change) in the mimic in vivo environ-
ment, is shown in Figure 3.3 A, B. The degradation of the SCL hydrogel groups varied (Figure 3.3
A). Specifically, in the first 96 h, the 0.8% SCL hydrogel degraded the fastest, the 2% SCL hy-
drogel degraded the slowest, and the 1.1% and 1.5% SCL hydrogels had similar degradation rates,
that were slightly slower than the 2% SCL hydrogel. Thereafter, the hydrogels in all four groups
disappeared, indicating complete degradation. In contrast, all four Ca2+ hydrogels demonstrated
similar trends and degradation rates in the presence of the enzyme (collagenase type II), until they
disappeared completely. This indicates that their degradation is solely a function of time and is not
affected by the concentration of alginate.
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The varying degradation rates across the SCL hydrogel groups is likely due to their different
mechanical strengths. The hydrogels with the lowest mechanical strength degraded the fastest,
whereas the hydrogels with a higher mechanical strength degraded more slowly. In contrast, all
Ca2+ hydrogels degraded more slowly than the SCL hydrogels, due to their collectively higher
mechanical strengths. This suggests that all of the Ca2+ hydrogels were strong enough to resist
the action of the enzyme, as reflected in the rather slow rate of degradation; thus, the only factor
affecting the degradation rate was time. The 2% SCL hydrogels, the strongest of the SCL hydrogels,
demonstrated the slowest degradation rate, and only a slight weight loss in the first 48 h after
exposure to the enzyme.
Figure 3.3: Degradation profiles of SCL and Ca2+ hydrogels. 0.8%, 1.1%, 1.5%, and 2% are
the concentrations of alginate in both types of hydrogels, and the varying concentrations of
alginate present for the different groups of hydrogels. (A) The mass change of SCL hydrogels
with hours. (B) The mass change of Ca2+ hydrogels with hours.
3.4.4 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) Stain-
ing
The percentage of living cells at 0 h, 2 h, 24 h, and two months after encapsulation in the hydrogels
are presented in Figure 3.4. Specifically, the cell viability right after the injection process was
measured and set as the baseline for the comparison with those measured at different time periods,
which is shown as a percentage thereof.
For the SCL hydrogels, data from 2 h after encapsulation show that cell viability decreases
with an increasing alginate concentration. Specifically, the 2% SCL hydrogels had the lowest cell
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viability and the 0.8% SCL hydrogels had the highest. This suggests that cell viability during the
injection process varies with hydrogel viscosity, with more cells surviving in the lower viscosity
hydrogels. After 24 h, the percentage of living cells in all of the groups increased, compared to
those at 0 h, particularly the 1.5% and 2% SCL hydrogels (t-test, p<0.01), which had a higher
cell viability than the other two groups. The increased number of living cells indicates that cells
proliferated after being encapsulated in the hydrogels, and the low cell viability in lower viscos-
ity hydrogels indicates that the cells survived better in the higher viscosity hydrogels. After two
months, cell numbers decreased compared to those at 2 h and 24 h, and 0.8% SCL hydrogels had
the lowest living cells rate out of all of the groups (t-test, p<0.05). This indicates that living cell
rates decreased with the degradation of hydrogels, due to a lack of protection.
For the Ca2+ hydrogels, cell viability, assessed by MTT assay, was not significantly different
across the four groups after 2 h (t-test), and all viability rates were less than those for the SCL
hydrogels (t-test, p<0.05). This indicates a lower retention rate of living cells in Ca2+ hydrogels,
which have a higher viscosity than the SCL hydrogels, during the cell encapsulation process. After
24 h, the cell viability sharply increased compared to the baseline, especially for the 1.1% Ca2+
hydrogel, which had the highest cell viability (t-test, p<0.01). As such, cells seem to prefer hydro-
gels with a higher mechanical strength, in order to survive and proliferate. After two months, cell
viability rates in the Ca2+ hydrogels still demonstrated an increasing trend, when compared to both
the baseline and 24 h values. In particular, the 1.1% Ca2+ hydrogel had the highest living cell rate
among the four groups. This suggests that cells were effectively regenerated during extended culti-
vation in hydrogels and proliferated the most in the high mechanical strength 1.1% Ca2+ hydrogels.
After two months, the living cell rates for all Ca2+ hydrogels were much higher than those for SCL
hydrogels. This reflects the fact that Ca2+ hydrogels have a slower degradation process than SCL
hydrogels and that cells are still protected in the hydrogels after two months. We speculate that,
during these two months, the cells proliferated and interconnected to each other, forming a network
structure similar to the ECM that provides protection for cells in in vivo conditions.
The mechanical properties of hydrogels are important factors affecting the cell viability, as
discussed above. It should be noted that, in addition to the mechanical properties, many other
factors, such as the presence of residual reagents, pore density, and apoptotic potential of gelatin
fragments, may also contribute to the cell viability.
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Figure 3.4: The percentage of living cells in SCL and Ca2+ hydrogels at different time in-
tervals measured by absorbance of optical density at 595 nm using MTT assay. 0.8%, 1.1%,
1.5%, and 2% are the concentrations of alginate in both types of hydrogels. t-test was used
to test the statistical significance.
3.4.5 Fluorescent Staining
The cells were stained with PI (red)/calcein (green)/DAPI (blue) to indicate dead cells/live cells/cell
nuclei. The images were captured via confocal microscopy and are shown in Figure 3.5, for only
one layer of cells in the hydrogels. There are staining in other adjacent layers got mixed to the
current layer despite lower concentrations of stains being applied to minimize misleading color
from adjacent layers during measurement. The proportion of the number of green cells to the
number of red cell in the SCL hydrogels was, in general, less than in the Ca2+ hydrogels, which
indicates that the cell survival rate in the Ca2+ hydrogels is higher than in the SCL hydrogels.
3.5 Limitations and Future Work
Cell differentiation from MDSCs into cardiomyocytes is important for MI repair. In this work,
cell differentiation from MDSCs into cardiomyocytes was not experimentally tested, as we only
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Figure 3.5: Fluorescent staining of live/dead cells in SCL and Ca2+ hydrogels. 0.8%, 1.1%,
1.5%, and 2% are the concentrations of alginate in both types of hydrogels, and the varying
concentrations of alginate present for the different groups of hydrogels.
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focused on optimizing the cell survival rate by adjusting the hydrogel formulation. In future work,
we will study how MDSCs differentiate into cardiomyocytes and compensate for diminished viable
cell numbers in MI hearts. Different stimulations inducing cell differentiation will be analyzed and
the beating ability of differentiated cells will also be evaluated.
3.6 Conclusions
Injecting hydrogel-encapsulated cells shows promise for compensating for the loss of cardiomy-
ocytes in MI repair. In this paper, we present a study on two types of alginate hydrogels, self-
crosslinked and calcium-ion cross-linked hydrogels (or SCL and Ca2+ hydrogels), to encapsulate
muscle-derived stem cells for potential MI repair. Our results illustrate that the cells can survive
and proliferate in both hydrogels over the examined time period, from their injection to two-month
cultivation. Our results also illustrate that cells have a better viability in SCL hydrogels than Ca2+
hydrogels right after injection and for the first 24 h after encapsulation. However, the cell sur-
vival rate is much higher in Ca2+ hydrogels than in SCL hydrogels after long-term (two month)
cultivation. Our efforts to select the best formation of hydrogel for optimizing cell survival, show
that SCL hydrogels with 0.8% alginate and 20% gelatin achieve the best cell viability during the
injection process. However, Ca2+ hydrogels with 1.1% alginate and 20% gelatin have the highest
cell survival rate during long-term cultivation, which is promising for the high-level regeneration
of cells for potential MI repair.
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4 Conclusions and Future Work
4.1 Summaries and Conclusions
In this study, two tissue-engineering strategies, as controlled release of BIO + IGF-1 via pH sen-
sitive hydrogel system and encapsulating living cells with alginate hydrogel for repairing MI were
developed and studied in Chapter 2 and Chapter 3, respectively. Experiments were designed and
performed in accordance to these strategies. Based on experimental results obtained, main conclu-
sions can be drawn as below.
4.2 Conclusions from Chapter 2
Chapter 2 presents the study on the sustained release of BIO and IGF-1 in a pH sensitive hydrogel
simulating endogenous cardiac repair in MI rats. Gelatin nanoparticles encapsulating BIO and/or
IGF-1 were fabricated successfully. In this novel hybrid hydrogel system, the gelatin nanoparticles
were efficiently cross-linked with the oxidized alginate, which was developed to deliver the grow
factors specifically to the MI site. Then the characteristics of nanoparticles and hydrogel system
were investigated and described. The controlled release profile of the growth factors was described.
From the in vivo results, the hybrid hydrogel system can enhance the proliferation of resident car-
diac cells as well as promoting revascularization around the MI sites, allowing improved cardiac
function and resulting in enhanced heart function recovery. These findings indicate that the hybrid
hydrogel system can co-deliver BIO and IGF-1 to MI areas and thus repair cardiac function by
promoting the regeneration of cardiomyocytes and revascularization. And this novel hybrid hydro-
gel delivery system is holding promise for treating MI and other related diseases requiring specific
concentrations of drugs given the ability of delivery a wide range of therapeutics.
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4.3 Conclusions from Chapter 3
Chapter 3 presents the study of encapsulating living cells in injectable alginate hydrogel for po-
tential MI animal repair. Two types of alginate hydrogels as self-crosslinking (SCL) and calcium
ion crosslinking (Ca2+ ) with varying formulations were fabricated successfully. Living muscle-
derived stem cells (MDSCs) were encapsulated in both types of hydrogels, and the experimental
results illustrate that these living cells were able to survive and proliferate from the moment of en-
capsulating and until two months after encapsulation in both hydrogels. The compositions of both
hydrogels were selected by evaluating the encapsulated living cells performance for further opti-
mizing cell viability during the injection process and the live/dead cell rate in long-term cultivation.
The characterization of both types of hydrogels was described, the morphology was characterized
by scanning electronic microscopy (SEM) and the mechanical properties were examined via a
rheometer. The experimental results of examined cell survival rate demonstrate that cells have a
better viability in SCL hydrogels than Ca2+ hydrogels right after injection and for the first 24 h
after encapsulation, especially the SCL hydrogel with a 0.8% alginate and 20% gelatin formulation
which had the highest cell viability during the injection process. However, the cell survival rate is
much higher in Ca2+ hydrogels than in SCL hydrogels after long-term cultivation, particularly, the
Ca2+ hydrogel composed of 1.1% alginate and 20% gelatin maintained the highest cell survival rate
after two months in culture. The cell survival rate after long-term cultivation shows promise for the
high-level regeneration of cells for potential MI repair.
4.4 Future Work
In this thesis, two strategies were developed based on injectable hydrogel, i.e., 1) combining with
nanoparticles for controlled release of growth factors and 2) encapsulating living cells for MI repair
had been studied. The experimental results obtained from both strategies which shows in chapter 2
and 3 are promising in MI repair.
It is noted that the research of strategy 1) was performed both in vitro and in vivo and that the
development of strategy 2) was pursued only in vitro though results showed promise for potential
MI repair. While the research in MI animal models is yet to be studied for strategy 2). Thus, for
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future work, the in vivo experiments of injectable hydrogel encapsulating living muscle derived
stem cells shall be performed. The research objectives should be to study the living cells’ behavior
and how this strategy works in animal’s hearts.
Specifically, the first step is to investigate whether the transplanted muscle derived stem cells
can undergo differentiation into other types of cells and what would be the conditions for potential
differentiation in vivo. From literature review, muscle derived stem cells are able to differentiate
into cardiomyoycytes with proper stimulations in vitro. But there is rare reference showing these
stem cells can differentiate into cardiomyocytes in animals’ MI repair. Hence, to investigate the
stimulations as specific conditions for MDSCs for potential differentiation is highly recommended.
There are two main proposed clues as physically stimulation and chemical drugs/growth factors
for stimulating MDSCs differentiating into cardiomyocytes. In details, to investigate whether sim-
ply physical stimulation of adding pressures on these cells can stimulate them differentiation. If
these cells were able to differentiate under physical stimulation, then the load range that can cause
the differentiation could be studied. The other possible clue to study the differentiation is proper
chemical molecules. For example, the specific family of growth factors should be chosen from huge
numbers of growth factors and the proper concentration of these chosen growth factors should be
determined.
From my preliminary experiments results on the differentiation of 3D cultivated muscle-derived
stem cells with growth factor TGF-b of the concentration at 2.5ng/ml and 5 ng/ml, it showed there
were cells stimulated into cardiomyocytes since the cardiac specific protein TnT after 14 days
cultivation with TGF-b at 5 ng/ml was examined. For future work, researchers may continue in-
vestigate the specific concentration of TGF-b for muscle-derived stem cells differentiation and the
appropriate cultivation time of the growth factor with cells.
The second step is to study the in vivo tests. Although 3D cultured cells with proper stimulation
for cells to differentiate into cardiomyocytes is the mimic of the in vivo, the real environment in
body can make huge differences due to the existence of various enzymes and their kinetic profile.
Thus to investigate whether muscle-derived stem cells can be differentiate into cardiomyoyctes is
important. Briefly, the study can be performed in MI animal hearts by transplanting MDSCs with
growth factors for some weeks and then examine whether there is the expression of cardiac tissue
specific antibody. In general, this study can start with the cultivation of GFP-labeled (green fluo-
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rescent protein) muscle-derived stem cells with growth factors for a few days until the expression
of specific protein can be examined. Then the growth factors could be released in a controlled man-
ner via nanoparticles to maintain their specific functioning concentration. And these differentiated
cells with the nanoparticles encapsulated growth factors to be transplanted into MI animals’ hearts
for few days then examine the heart of these transplanted GFP cells to see whether there is the
expression of cardiac specific protein.
The last step is to investigate the integrated effects of hydrogel with living cells in MI animals.
The enhanced function of MI hearts can be achieved through either proliferated cardiomyocytes and
differentiated cardiomyocytes, or the angiogenesis of the small arteries which can provid blood-
efficient environment for cells to survive. Thus, to examine whether the combination of living
cells combining hydrogels with growth factors works in regeneration ability of cardiomyocytes and
the revascularization ability after transplanting into MI animal hearts is important. The combining
system of hydrogel with living cells and growth factors should be fabricated and examined before
transplanting into MI animals’ hearts.
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